Ads by Google
Tykerb could be the much expected breast cancer drug as Glaxo is set to file for EU approval of breast cancer drug Tykerb.
Women age 65 years or older constitute half of new breast cancer patients each year, and the number of older women with breast cancer is forecast to double by 2030 as the baby boomers age.
Results from a recent survey of European women with early breast cancer show that the information needs of patients are not being met and that there is an unacceptably low level of patient involvement in potentially life extending treatment decisions.
The breast cancer campaign will run throughout the months of October and November, aiming to reach out to as many women as possible.
The Government of Australia has accepted a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) to list the breast cancer treatment drug trastuzumab (Herceptin) on the Pharmaceutical Benefits Scheme (PBS).
Nicole Kidman stresses the importance for the women to understand breast cancer and learn about the disease.
The number of breast cancer cases has risen considerably shows the data released by the Office for National Statistics and reported by the Cancer Research UK.
Computers aid cutting the work of radiologist and helping breast cancer screening.
One in seven women will develop breast cancer in her life, but how much do most women know about breast cancer?
How the estrogen hormone can help keep breast cancer cells alive.
Stress reduction, drug therapy, may prevent chronic problems after breast cancer surgery.
Aromatase inhibitors improve the survival of advanced breast cancer patients compared to standard hormone therapies like tamoxifen.
Drugmaker GlaxoSmithKline has submitted experimental breast cancer drug Tykerb for approval in the U.S. for use in the treatment of advanced breast cancer.
In combination with chemotherapy, Tykerb improves time to breast cancer progression, based on a phase III study.
Researchers have studied if OncoPlan can help identify breast cancer patients who would benefit most from chemotherapy.
Women with breast cancer who reported the highest levels of physical activity in the year before they were diagnosed with breast cancer may have higher survival.
A new breast cancer screening tool for the general practitioner effectively identifies patients at risk for hereditary breast cancer.
For determining if and how far breast cancer has spread into the breast ducts MRI is better than MDCT and should be used before patients receive breast conserving therapy.
The researchers present a model for the selective uptake of BPA into breast cancer cells by implicating human enzymes that sulfate and de sulfate BPA.
It is vital that women with breast cancer do not deny themselves the chance of the maximum possible benefit from their medication treatment.
Whole body positron emission tomography (PET) scans could help physicians determine whether breast cancer has spread to the lymph nodes in the armpit prior to surgery.
Finding may help women get more effective breast cancer treatment.
Breast cancer patients 63 years of age or younger may experience more chemotherapy related serious adverse effects than reported in clinical trials.
The majority of breast cancer cases are caused by genetic changes that occur during a woman's lifetime, but researchers estimate inherited mutations play a role in anywhere from 5 to 27% of all breast cancer cases.
Glucobrassicin has been found to be effective against breast cancer.
Breast cancer survivors' beliefs about what may have caused their cancer are connected to whether they make healthy lifestyle changes after a cancer diagnosis.
The monoclonal antibody Herceptin (trastuzumab) used in combination with certain cancer chemotherapies effectively treats breast cancer tumors.
DES exposed women are developing the typical range of breast cancers after age 40 at a faster rate than non exposed women of the same ages.
Cancer cells present after additional surgery for breast cancer may predict whether a woman will see her cancer return.
A woman's risk of breast cancer in her lifetime may be tripled by a specific variation in the CHEK2 gene.
